Zenarestat

Drug Profile

Zenarestat

Alternative Names: FK 366; FR 74366; FR 901366

Latest Information Update: 29 Aug 2009

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Pfizer
  • Class Antihyperglycaemics; Quinazolines; Small molecules
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 23 Oct 2002 A clinical study has been added to the Diabetes pharmacodynamics section
  • 18 Oct 2000 Early results from analysis of phase III trials have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top